Scienture Holdings, Inc. quarterly report, Q2 FY2017

Business context and reporting period

The supplied filing is Trxade Group, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2017—not a filing identified as Scienture Holdings, Inc. Trxade operates a web-based business-to-business marketplace connecting independent pharmacies and pharmaceutical suppliers. Its Westminster Pharmaceuticals distribution division was sold in December 2016 and is reported as discontinued operations.

Key financial results

Gross margin was 100% in 2017 because reported cost of sales was zero. Six-month operating expenses were $1,260,438, including $164,777 of warrant and option expense; interest expense was $105,837 and the debt-extinguishment loss was $11,512. The three-month net loss was from continuing operations; the comparable 2016 periods also included losses from discontinued operations.

At June 30, 2017, cash was $103,204, current assets were $423,891, current liabilities were $655,973, and working capital was negative $232,082. Total liabilities were $1,060,025, versus $1,485,181 at December 31, 2016; shareholders’ deficit was $636,134. The filing reports $337,065 of short-term debt in its liquidity discussion. Cash increased by $88,525 during the first half, including $86,949 from financing activities; the company issued $250,000 of common stock and received $180,000 in related-party note proceeds, while repaying third-party promissory notes.

Material changes and management commentary

• Six-month revenue rose about 18% year over year; management attributed the increase to platform fee income, transition fees related to the Westminster sale, and customer growth through marketing and training.
• Operating income improved from a loss to a profit, which management attributed in part to lower employee cash compensation and lower general and administrative expense.
• Management stated that the company needs additional funding to develop its platform, grow its customer base, and meet operating needs. Estimated general and administrative and working-capital requirements for the next 12 months were approximately $2.425 million.
• The company disclosed substantial doubt about its ability to continue as a going concern, citing recurring operating losses and dependence on additional capital and future profitable operations. It cautioned that financing may not be available on favorable terms or at all.
• Management and board members were counterparties to related-party borrowing arrangements. Two executives suspended salaries through June 30, 2017; the CEO’s salary resumed in June.

Risks, contingencies, and unusual items

• Disclosure controls and procedures were reported as ineffective at June 30, 2017. The company reported no material change in internal control over financial reporting during the six-month period.
• A class-action “junk fax” settlement of $200,000 was funded in March 2017; the filing reports no other legal proceedings in Part II.
• In July 2017, after the reporting date, the company documented three-year related-party notes totaling $180,000, bearing 6% interest. The filing also describes related-party obligations and their classification between current and long-term debt.
• There were no reported off-balance-sheet arrangements, and management reported no change in risk factors from the 2016 Form 10-K.

Important facts for investors to verify

• Confirm the issuer: the provided text is for Trxade Group, Inc., despite the request metadata naming Scienture Holdings, Inc.
• Reconcile the debt balances, working-capital presentation, and related-party note classification, including the July 2017 post-period arrangements.
• Assess the company’s ability to fund the stated $2.425 million of anticipated 12-month requirements and whether additional financing is available.
• Review the causes and remediation plans for ineffective disclosure controls.
• Evaluate the durability and composition of revenue growth, including transition fees associated with the Westminster sale.